Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Inhibition of telomerase is proposed to limit the growth of cancer cells by triggering telomere shortening and cell death. Telomere maintenance by telomerase is sufficient, in some cell types, to allow immortal growth. Telomerase has been shown to cooperate with oncogenes in transforming cultured primary human cells into neoplastic cells, suggesting that telomerase activation contributes to malignant transformation. Moreover, telomerase inhibition in human tumour cell lines using dominant-negative versions of TERT leads to telomere shortening and cell death. These findings have led to the proposition that telomerase inhibition may result in cessation of tumour growth. The absence of telomerase from most normal cells supports the potential efficacy of anti-telomerase drugs for tumour therapy, as its inhibition is unlikely to have toxic effects. Mice deficient for Terc RNA (encoding telomerase) lack telomerase activity, and constitute a model for evaluating the role of telomerase and telomeres in tumourigenesis. Late-generation Terc-/- mice show defects in proliferative tissues and a moderate increase in the incidence of spontaneous tumours in highly proliferative cell types (lymphomas, teratocarcinomas). The appearance of these tumours is thought to be a consequence of chromosomal instability in these mice. These observations have challenged the expected effectiveness of anti-telomerase-based cancer therapies. Different cell types may nonetheless vary in their sensitivity to t…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“findings consistent with previous studies establishing that telomere dysfunction acts as a tumor suppressor when p53 function is intact (7, 8, 30, 48).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [48]
In the citing paper
“Loss of telomerase activity in mice has been shown to suppress tumorigenesis in various tumour models [13][14][15][16]”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [13]
In the citing paper
“In a transgenic breast cancer model driven by Polyoma Middle T antigen, telomere dysfunction significantly impaired not only tumor latency and penetrance but also reduced metastatic potential (90).”
From Telomeres and telomerase in cancer (2010) · cites this paper as [90]
In the citing paper
“A similar finding was observed in a skin carcinogenesis model, in which late generation mTerc−/− mice produced 20-fold fewer skin tumors upon chemical carcinogenesis treatment of the skin compared to wild-type controls with long telomeres50.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [50]
Citations
Cites
Extension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Self-citationLongevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice
Rudolph, K. L., Chang, S., Lee, H.-W., Blasco, M., Gottlieb, G. J., Greider, C., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80580-2 · Cited by 1,349
Self-citationTelomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279
Essential role of mouse telomerase in highly proliferative organs
Lee, H.-W., Blasco, M. A., Gottlieb, G. J., Horner, J. W., Greider, C. W., & DePinho, R. A. (1998) · Nature · doi:10.1038/33345 · Cited by 1,270
Self-citationKiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., & Klingelhutz, A. J. (1998) · Nature · doi:10.1038/23962 · Cited by 1,206
Inhibition of telomerase limits the growth of human cancer cells
Hahn, W. C., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Kurachi, A., Beijersbergen, R. L., Knoll, J. H. M., Meyerson, M., & Weinberg, R. A. (1999) · Nature Medicine · doi:10.1038/13495 · Cited by 1,030
Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80762-x · Cited by 979 · cited 1×
“The appearance of these tumours is thought to be a consequence of chromosomal instability in these mic”
Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis
Quintanilla, M., Brown, K., Ramsden, M., & Balmain, A. (1986) · Nature · doi:10.1038/322078a0 · Cited by 859 · cited 1×
“H-RAS activation and telomerase upregulation are reported to occur in most DMBA-initiated papilloma”
Background
Research works printed but not linked: 1
- Hennings, H. Primary culture of keratinocytes from newborn mouse epidermis in medium with lowered levels of Ca2+. in Keratinocyte Methods (eds Leigh, I.M. & Watt, F.M.) 21–23 (Cambridge University Press, New York, 1994).
Cited by
Items 101–200 of 348
Telomerase: regulation, function and transformation
Dong, C. K., Masutomi, K., & Hahn, W. C. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.12.005 · Cited by 100
Short telomeres protect from diet‐induced atherosclerosis in apolipoprotein E‐null mice
Poch, E., Carbonell, P., Franco, S., Díez‐Juan, A., Blasco, M. A., & Andrés, V. (2004) · The FASEB Journal · doi:10.1096/fj.03-0710fje · Cited by 94
“Notably, mice with critically short telomeres are also less predisposed to tumor development (32, 37).”
BackgroundMethodSelf-citationCanela, A., Martín-Caballero, J., Flores, J. M., & Blasco, M. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.10.4275-4293.2004 · Cited by 90
“This role led to the proposition that in the absence of telomerase, short telomeres can act as tumor suppressors, thus encouraging the use of telomerase inhibitors as potential anticancer drugs in combination with other chemotherapeutic or radiotherapeutic agents (4, 6, 15, 27).”
BackgroundSelf-citationUsing naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology
Pang, L. Y., & Argyle, D. J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.02.010 · Cited by 105
“Studies in mTerc−/− mice showed that telomere shortening enhanced tumour initiation but suppressed tumour progression [80,84,85].”
BackgroundTelomerase and its potential for therapeutic intervention
Phatak, P., & Burger, A. M. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707374 · Cited by 90
“Particularly useful to validate telomerase as a cancer inhibitory target were studies with hTERC knockout mice and ectopic expression of dominant-negative hTERT in human tumour cells (Blasco et al., 1997; Hahn et al., 1999b; Gonzalez-Suarez et al., 2000).”
BackgroundNiwa, O., Barcellos‐Hoff, M. H., Globus, R. K., Harrison, J. D., Hendry, J. H., Jacob, P., Martin, M. T., Seed, T. M., Shay, J. W., Story, M. D., et al. (2015) · Annals of the ICRP · doi:10.1177/0146645315595585 · Cited by 102
“Senescence acts as a powerful block for carcinogenesis, as telomerase-deficient mice were found to resist chemical induction of skin cancer (Gonzalez-Suarez et al., 2000).”
BackgroundSignaling through estrogen receptors modulates telomerase activity in human prostate cancer
Nanni, S., Narducci, M., Pietra, L. D., Moretti, F., Grasselli, A., Carli, P. D., Sacchi, A., Pontecorvi, A., & Farsetti, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15552 · Cited by 101
Chromatin regulation and non-coding RNAs at mammalian telomeres
Schoeftner, S., & Blasco, M. A. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.09.015 · Cited by 104
Self-citationTelomere repeat binding factors: keeping the ends in check
Karlseder, J. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00706-1 · Cited by 105
“Furthermore, it was shown that these short telomeres confer resistance against skin tumorigenesis [2] and lead to a decline in the multiplicity and size of macroscopic adenomas [3].”
BackgroundFranco, S., Segura, I., Riese, H. H., & Blasco, M. A. (2002) · PubMed · Cited by 96
Self-citationEspejel, S., Klatt, P., Murcia, J. M.-D., Martín-Caballero, J., Flores, J. M., Taccioli, G., de Murcia, G., & Blasco, M. A. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200407178 · Cited by 88
“In line with our previous observation that short telomeres can act as tumor suppressors (Gonzalez-Suarez et al., 2000), comparisons of G3 Terc / /Ku86 / mice (1.5% developed tumors) with the corresponding G1 (7.8%, P 0.05) or wild-type (10.0%, P 0.04) cohorts revealed a significant reduction of…”
BackgroundResultInfluentialSelf-citationp16INK4a as a Second Effector of the Telomere Damage Pathway
Jacobs, J. J. L., & de Lange, T. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2104 · Cited by 87
Modulation of telomere protection by the PI3K/AKT pathway
Méndez‐Pertuz, M., Martínez, P., Blanco‐Aparicio, C., Gómez‐Casero, E., García, A. B., Martinez-Torrecuadrada, J. L., Palafox, M., Cortés, J., Serra, V., Pastor, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01329-2 · Cited by 104
Self-citationToussaint, O., Dumont, P., Remacle, J., Dierick, J.-F., Pascal, T., Frippiat, C., Magalhaes, J. P., Zdanov, S., & Chainiaux, F. (2002) · The Scientific World JOURNAL · doi:10.1100/tsw.2002.100 · Cited by 86
“In agreement with this concept, the activation of p53 is the mediator of senescence induced by short telomeres[31,32].”
BackgroundDo tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence?
Pelicci, P. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420750 · Cited by 85
Postnatal telomere dysfunction induces cardiomyocyte cell-cycle arrest through p21 activation
Aix, E., Gutiérrez-Gutiérrez, Ó., Sánchez-Ferrer, C., Aguado, T., & Flores, I. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201510091 · Cited by 84
“Slides were then fixed in 4% formaldehyde for 20 min and hybridized with a Cy3-labeled peptide nucleic acid probe targeting the telomere repeat sequence (Zijlmans et al., 1997; Herrera et al., 1999; González-Suárez et al., 2000; Flores et al., 2008).”
Flores, I., & Blasco, M. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004934 · Cited by 83
“The tumor suppressor protein p53 is activated and mediates the cellular response to various types of DNA damage, including telomere dysfunction”
BackgroundSelf-citationImmortalization and Transformation of Human Cells
C. Hahn, W. (2002) · Molecules and Cells · doi:10.1016/s1016-8478(23)15045-x · Cited by 84
Kallikrein-related peptidases (KLKs) and the hallmarks of cancer
Filippou, P. S., Karagiannis, G. S., Musrap, N., & Diamandis, E. P. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2016.1154643 · Cited by 89
Short-term gain, long-term pain: the senescence life cycle and cancer
Chan, A. S. L., & Narita, M. (2019) · Genes & Development · doi:10.1101/gad.320937.118 · Cited by 80
“The tumor-suppressive role of telomere shortening is recapitulated in telomerase deficiency in various tumor-prone mouse models (González-Suárez et al. 2000; Blasco 2005).”
BackgroundCancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2
Cherfils‐Vicini, J., Iltis, C., Cervera, L., Pisano, S., Croce, O., Sadouni, N., Győrffy, B., Collet, R., Renault, V. M., Rey‐Millet, M., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100012 · Cited by 87
“…antagonistic outcomes; it both favors cancer initiation through mechanisms involving genome instability (Artandi et al , 2000) and prevents cancer progression by activating the DNA Damage Response (DDR) checkpoint to behave as a cell-intrinsic proliferation barrier (Gonza´lez-Sua´rez et al , 2000).”
Mimeault, M., & Batra, S. K. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2008.12.001 · Cited by 85
Telomerase-independent Regulation of ATR by Human Telomerase RNA
Kedde, M., le Sage, C., Duursma, A. M., Zlotorynski, E., van Leeuwen, B., Nijkamp, W., Beijersbergen, R. L., & Agami, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607676200 · Cited by 86
Bejarano, L., Schuhmacher, A. J., Méndez, M., Megías, D., Blanco‐Aparicio, C., Martínez, S., Pastor, J., Squatrito, M., & Blasco, M. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.006 · Cited by 82
“However, both telomerase abrogation in mouse cancer models and human clinical trials with telomerase inhibitors have shown limited benefit, as telomerase inhibition only affects cell viability when telomeres are short, and tumors are heterogeneous in terms of telomere length (Middleton et al., 2014; Parkhurst et al.,…”
BackgroundInfluentialSelf-citationCayuela, M. L., Flores, J. M., & Blasco, M. A. (2005) · EMBO reports · doi:10.1038/sj.embor.7400359 · Cited by 76
“We also confirmed our previous observation that first-generation Terc / mice are slightly less susceptible to skin tumorigenesis than wild-type controls (González-Suárez et al, 2000).”
BackgroundResultSelf-citationTelomere-related Markers for Cancer
Yuan, X., Dai, M., & Xu, D. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200106145340 · Cited by 88
Signaling through estrogen receptors modulates telomerase activity in human prostate cancer
Nanni, S., Narducci, M., Pietra, L. D., Moretti, F., Grasselli, A., Carli, P. D., Sacchi, A., Pontecorvi, A., & Farsetti, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215552 · Cited by 81
Masutomi, K., & Hahn, W. C. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00703-6 · Cited by 83
“[69] E.”
BackgroundThe mTOR pathway is necessary for survival of mice with short telomeres
Ferrara-Romeo, I., Martinez, P., Saraswati, S., Whittemore, K., Graña-Castro, O., Thelma Poluha, L., Serrano, R., Hernandez-Encinas, E., Blanco-Aparicio, C., Maria Flores, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14962-1 · Cited by 73
Self-citationAttardi, L. D. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.04.019 · Cited by 87
Geserick, C., Tejera, Á. M., González‐Suárez, E., Klatt, P., & Blasco, M. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209465 · Cited by 83
Self-citationTelomerase Maintains Telomere Structure in Normal Human Cells
Masutomi, K., Yu, E. Y., Khurts, S., Ben-Porath, I., Currier, J. L., Metz, G. B., Brooks, M. W., Kaneko, S., Murakami, S., DeCaprio, J. A., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00550-6 · Cited by 70
Whittemore, K., Derevyanko, A., Martinez, P., Serrano, R., Pumarola, M., Bosch, F., & Blasco, M. A. (2019) · Aging · doi:10.18632/aging.101982 · Cited by 69
“Paraffin-embedded tissue sections were hybridized with a PNA-telomeric Cy3 probe, and fluorescence intensity of telomeres was determined as described previously [118,119].”
MethodSelf-citationPlentz, R. R., Wiemann, S. U., Flemming, P., Meier, P. N., Kubicka, S., Kreipe, H., Manns, M. P., & Rudolph, K. L. (2003) · Gut · doi:10.1136/gut.52.9.1304 · Cited by 70
Qi, L., Strong, M. A., Karim, B. O., Armanios, M. Y., Huso, D. L., & Greider, C. W. (2003) · PubMed · Cited by 79
Control of Cellular Aging, Tissue Function, and Cancer by p53 Downstream of Telomeres
Roake, C. M., & Artandi, S. E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026088 · Cited by 67
“In this model, treatment of G5 TERC2/2 mice with DMBA/TPA led to a 20-fold lower rate of papilloma development than in WT mice and a 16-fold lower rate than in G1 TERC 2/2 animals, suggesting that, in this context, short telomeres are protective against carcinogenesis (Gonzalez-Suarez et al. 2000).”
Lechel, A., Holstege, H. H., Begus, Y., Schienke, A., Kamino, K., Lehmann, U., Kubicka, S., Schirmacher, P., Jonkers, J., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.045 · Cited by 75
Siegl-Cachedenier, I., Flores, I., Klatt, P., & Blasco, M. A. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704141 · Cited by 64
“JCB • VOLUME 179 • NUMBER 2 • 2007 278 wound healing, hair loss, and hair graying (Lee et al., 1998; Herrera et al., 1999; Rudolph et al., 1999), as well as decreased skin cancer, as indicated by the fact that they are resistant to skin carcinogenesis protocols (Gonzalez-Suarez et al., 2000).”
InfluentialSelf-citationSenescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword
Battram, A. M., Bachiller, M., & Martín-Antonio, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124346 · Cited by 70
Telomere shortening produces an inflammatory environment that increases tumor incidence in zebrafish
Lex, K., Maia-Gil, M., Lopes-Bastos, B., Figueira, M., Marzullo, M., Giannetti, K., Carvalho, T., & Ferreira, M. G. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920049117 · Cited by 62
“Previous studies suggest that telomere dysfunction triggers higher tumor initiation (8, 9), yet subsequent tumor progression appears to be limited, at least, partially, in the absence of telomerase (10, 11) and only fully active if telomerase is restored (12, 13).”
BackgroundModeling chromosomal instability and epithelial carcinogenesis in the telomerase-deficient mouse
Chang, S. S., Khoo, C., & DePinho, R. A. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0374 · Cited by 71
Pot1 OB-fold mutations unleash telomere instability to initiate tumorigenesis
Gu, P., Wang, Y., Bisht, K. K., Wu, L., Kukova, L., Smith, E. M., Xiao, Y., Bailey, S. M., Lei, M., Nandakumar, J., et al. (2016) · Oncogene · doi:10.1038/onc.2016.405 · Cited by 67
Generation of Telomeric G Strand Overhangs Involves Both G and C Strand Cleavage
Jacob, N. K., Kirk, K. E., & Price, C. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00131-x · Cited by 59
Multiple cancer pathways regulate telomere protection
Bejarano, L., Bosso, G., Louzame, J., Serrano, R., Gómez‐Casero, E., Martinez-Torrecuadrada, J. L., Martínez, S., Blanco‐Aparicio, C., Pastor, J., & Blasco, M. A. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910292 · Cited by 58
“…most likely due to the fact that a telomerase abrogation would only affect critically short telomeres, and tumors are heterogeneous in terms of telomere length (Chin et al, 1999; Greenberg et al, 1999; Gonzalez-Suarez et al, 2000; Parkhurst et al, 2004; Perera et al, 2008; Middleton et al, 2014).”
BackgroundSelf-citationStem cells, telomerase and dyskeratosis congenita
Mason, P. J. (2003) · BioEssays · doi:10.1002/bies.10229 · Cited by 65
Give me a break: How telomeres suppress the DNA damage response
Denchi, E. L. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.04.013 · Cited by 77
Telomeres and cancer: a tale with many endings
Blasco, M. A. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00011-4 · Cited by 62
Self-citationRaval-Fernandes, S., Kickhoefer, V. A., Ramirez, C. M., & Rome, L. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0770 · Cited by 72
“Similarly, telomerase-deficient mice with short telomeres were resistant to papilloma formation after chemical carcinogenesis of the skin (45).”
BackgroundRegulation of Senescence in Cancer and Aging
Kong, Y., Cui, H., Ramkumar, C., & Zhang, H. (2011) · Journal of Aging Research · doi:10.4061/2011/963172 · Cited by 69
“Decreased tumorigenesis is also observed in late generation of mice with a null mutation in telomere catalytic subunit (mTERT−/−), and p53 mutation enables tumor progression in these mice [141].”
BackgroundGarcía‐Beccaria, M., Martínez, P., Méndez‐Pertuz, M., Martínez, S., Blanco‐Aparicio, C., Cañamero, M., Mulero, F., Ambrogio, C., Flores, J. M., Megias, D., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404497 · Cited by 55
“Aberrant telomerase activation is a common feature of human cancers, where it allows the growth of malignant cells by ensuring maintenance of a minimal functional telomere length that permits cell division (Kim et al , 1994; Hahn et al , 1999; Gonzalez-Suarez et al , 2000).”
Self-citationImmunosenescence phenotypes in the telomerase knockout mouse
Blasco, M. A. (2002) · Springer Seminars in Immunopathology · doi:10.1007/s00281-001-0096-1 · Cited by 58
“In both genetic backgrounds the phenotypes associated to telomere dysfunction include (1) partial embryonic mortality due to a defect in the closure of the neural tube and to increased neuronal apoptosis [29]; (2) small size and severe intestinal atrophy [30, 54]; (3) spleen atrophy and reduced proliferation of B and…”
BackgroundSelf-citationKhoo, C. M., Carrasco, D. R., Bosenberg, M. W., Paik, J.-H., & DePinho, R. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700093104 · Cited by 52
Tümpel, S., & Rudolph, K. L. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06547.x · Cited by 54
Dynamic rearrangement of telomeres during spermatogenesis in mice
Tanemura, K., Ogura, A., Cheong, C., Gotoh, H., Matsumoto, K., Sato, E., Hayashi, Y., Lee, H., & Kondo, T. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2005.02.025 · Cited by 62
“After the elongated spermatid stage, the chromosomes of late spermatogenic cells become tightly packed with protamine, a histone-like protein, and such compaction of chromatin probably prevents the hybridization of probes with protocols previously reported (data not shown; Franco et al., 2002; Gonzalez-Suarez et al.,…”
MethodTelomerase as an emerging target to fight cancer — Opportunities and challenges for nanomedicine
Philippi, C., Loretz, B., Schaefer, U. F., & Lehr, C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.025 · Cited by 64
“Several studies comprising a variety of mechanistic approaches like mutations, RNA interference, translational inhibition or functional inhibition of the telomerase enzyme activity provided the proof of concept for this form of cancer treatment [18–24].”
BackgroundIannilli, F., Zalfa, F., Gartner, A., Bagni, C., & Dotti, C. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066602 · Cited by 53
Pepke, M. L., & Eisenberg, D. T. A. (2021) · Molecular Ecology · doi:10.1111/mec.15870 · Cited by 61
Precancer in Mice: Animal Models Used to Understand, Prevent, and Treat Human Precancers
Cardiff, R. D., Anver, M. R., Boivin, G. P., Bosenberg, M., Maronpot, R. R., Molinolo, A., Nikitin, A. Y., Rehg, J. E., THOMAS, G. V., Russell, R. G., et al. (2006) · Toxicologic Pathology · doi:10.1080/01926230600930129 · Cited by 55
“In late generation Terc-/- mice that possess short telomeres, precancerous squamous papillomas still occur at a reduced rate following topically applied DMBA/TPA, but progression to invasive carcinoma is prevented (Gonzalez-Suarez et al., 2000).”
BackgroundRankin, A. M., Faller, D. V., & Spanjaard, R. A. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f5d4c2 · Cited by 58
The complex interplay between aging and cancer
Trastus, L. A., & di Fagagna, F. D. (2025) · Nature Aging · doi:10.1038/s43587-025-00827-z · Cited by 65
“Accordingly, several reports show a protective role of telomerase inactivation in different cancer settings 97–99 , and, for this reason, telomerase inhibitors are being tested for anticancer treatments 60,100 .”
2009 Nobel Prize in Physiology or Medicine: telomeres and telomerase
Varela, E., & Blasco, M. A. (2010) · Oncogene · doi:10.1038/onc.2010.15 · Cited by 60
“, 2005) and telomerase knockout mice with short telomeres are resistant to carcinogenesis (González-Suárez et al., 2000) even in backgrounds with higher susceptibility to tumor emergence, such as mice defective for INK4a/Arf, p21, ATM, Ku, DNAPK or PMS2 (Greenberg et al.”
BackgroundSelf-citationSiegl-Cachedenier, I., Muñoz, P., Flores, J. M., Klatt, P., & Blasco, M. A. (2007) · Genes & Development · doi:10.1101/gad.430107 · Cited by 50
“These results are in agreement with short telomeres acting as potent tumor suppressors in the context of telomerase deficiency (González-Suárez et al. 2000; Blasco and Hahn 2003).”
BackgroundMethodResultInfluentialSelf-citationCanela, A., Klatt, P., & Blasco, M. A. (2007) · Methods in Molecular Biology · doi:10.1007/978-1-59745-361-5_5 · Cited by 49
Self-citationMiR‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer
Dinami, R., Pompili, L., Petti, E., Porru, M., D’Angelo, C., Vito, S. D., Rizzo, A., Campani, V., Rosa, G. D., Bruna, A., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216033 · Cited by 53
“First, telomerase inhibition only becomes efficient when telomeres have reached a critical length in tumors with wild type p53 (Gonz (cid:1) alez-Su (cid:1) arez et al , 2000; Perera et al , 2008).”
Telomere Length Influences Cancer Cell Differentiation In Vivo
Hirashima, K., Migita, T., Sato, S., Muramatsu, Y., Ishikawa, Y., & Seimiya, H. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00136-13 · Cited by 50
Martínez, P., Gómez-López, G., Pisano, D. G., Flores, J. M., & Blasco, M. A. (2016) · Aging Cell · doi:10.1111/acel.12517 · Cited by 47
“3E), in agreement with a potent tumor suppressor activity of short telomeres (Gonzalez-Suarez et al., 2000).”
BackgroundSelf-citationp53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis
Amaral, J. D., Castro, R. E., Steer, C. J., & Rodrigues, C. M. P. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.09.005 · Cited by 51
Telomerase and cancer: time to move from a promising target to a clinical reality
Keith, W. N., Evans, T. R. J., & Glasspool, R. M. (2001) · The Journal of Pathology · doi:10.1002/path.1001 · Cited by 55
“They also show relative resistance to multi-stage skin carcinogenesis [40].”
BackgroundThe Contribution of Epidermal Stem Cells to Skin Cancer
Gerdes, M. J., & Yuspa, S. H. (2005) · Stem Cell Reviews and Reports · doi:10.1385/scr:1:3:225 · Cited by 50
Soohoo, C., Shi, R., Lee, T. H., Huang, P., Lu, K. P., & Zhou, X. Z. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.180174 · Cited by 56
Gordon, K., Ireland, H., Roberts, M., Steeghs, K., McCaul, J. A., MacDonald, D. G., & Parkinson, E. K. (2003) · PubMed · Cited by 50
Potential of telomerase activation in extending health span and longevity
de Jesus, B. B., & Blasco, M. A. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.09.004 · Cited by 44
“This could be related to the fact that cells lacking telomerase are resistant to cancer initiation [50], mimicking the tumor suppressor situation and, somehow, can preserve this characteristic after a telomerase pulse, even in the presence of a higher genomic instability [49 ].”
BackgroundSelf-citationLiu, H., Liu, S., Wang, H., Xie, X., Chen, X., Zhang, X., & Zhang, Y. (2012) · Diagnostic Pathology · doi:10.1186/1746-1596-7-147 · Cited by 44
“Consistent with this study, several studies also highlighted the fact that both telomerase components restrict telomerase activity and telomere length in vitro, suggesting that the tumorigenic effects of hTERT overexpression are reliant on hTERC expression and in fact hTERT overexpression in an hTERC deficient backgro…”
BackgroundNon-canonical roles of canonical telomere binding proteins in cancers
Akıncılar, S. C., Chan, C. H. T., Ng, Q. F., Fidan, K., & Tergaonkar, V. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03783-0 · Cited by 47
“In a related study, TPA treated G5 TERC−/− mice, which have critically shorter telomeres, developed fewer papillomas when compared to G1 TERC−/− mice or wild-type mice [89].”
Lechel, A., Manns, M. P., & Rudolph, K. L. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.06.010 · Cited by 47
Identification of Telomere-Dependent “Senescence-like” Arrest in Mouse Embryonic Fibroblasts
Espejel, S., & Blasco, M. A. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5533 · Cited by 53
Self-citationTelomere dynamics in childhood leukemia and solid tumors: a follow-up study
Franco, S., Ozkaynak, M. F., Sandoval, C., Tugal, O., Jayabose, S., Engelhardt, M. M., & Moore, M. A. S. (2003) · Leukemia · doi:10.1038/sj.leu.2402815 · Cited by 46
Telomeric sequences, radiation sensitivity and genomic instability
Bouffler, S. D., Blasco, M. A., Cox, R., & Smith, P. J. (2001) · International Journal of Radiation Biology · doi:10.1080/09553000110069326 · Cited by 52
“Journal of CellBlasco, M. A., 2000, Short telomeres result in organismal sensitivity to ionizing radiation in mammals.”
BackgroundSelf-citationAnisimov, V. N. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00262-7 · Cited by 41
Muñoz-Lorente, M. A., Martínez, P., Tejera, Á., Whittemore, K., Moisés-Silva, A. C., Bosch, F., & Blasco, M. A. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007562 · Cited by 40
Self-citationMSH2 deficiency abolishes the anticancer and pro‐aging activity of short telomeres
Martinez, P., Siegl‐Cachedenier, I., Flores, J. M., & Blasco, M. A. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2008.00441.x · Cited by 40
“For Q-FISH analysis on small intestine sections, de-paraffinated sections were hybridized with a PNA-telomeric probe and telomere fluorescence was determined as previously described (Herrera et al., 1999; Gonzalez-Suarez et al., 2000).”
MethodSelf-citationTelomere shortening and cell fates in mouse models of neoplasia
Artandi, S. E. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02222-5 · Cited by 40
Telomerase inhibition and the future management of head-and-neck cancer
McCaul, J. A., Gordon, K., Clark, L., & Parkinson, E. K. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00729-5 · Cited by 44
Mimeault, M., & Batra, S. K. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00885.x · Cited by 38
“mice, which are deficient in telomerase, has been associated with an induction of senescence and apoptotic cell death and enhanced resistant to spontaneous skin tumorigenesis [170, 171].”
BackgroundTelomeres and Telomerase in Stem Cells during Aging and Disease
Ju, Z., & Rudolph, K. L. (2006) · KARGER eBooks · doi:10.1159/000092502 · Cited by 44
Genetic Analysis of Myc and Telomerase Interactions In Vivo
Flores, I., Evan, G., & Blasco, M. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00543-06 · Cited by 33
“This progressive telomere loss has been proposed to suppress tumorigenesis by limiting the replicative potential of cells (1, 2, 16).”
BackgroundSelf-citationCerezo, A., Stark, H., Moshir, S., & Boukamp, P. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12304.x · Cited by 41
Iglesias, M., Felix, D. A., Gutiérrez‐Gutiérrez, Ó., Miguel-Bonet, M. D. M. D., Sahu, S., Fernández-Varas, B., Perona, R., Aboobaker, A. A., Flores, I., & González‐Estévez, C. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.06.005 · Cited by 42
“Planarian StemCells Display HigherMedian Telomere Length Than Their Descendants We adapted TelQ-FISH or telomapping (Flores et al., 2008; Gonzalez-Suarez et al., 2000; Zijlmans et al., 1997) to asexual S.”
Telomerase RNA biosynthesis and processing
Smekalova, E. M., Shubernetskaya, O. S., Zvereva, M. I., Gromenko, E. V., Rubtsova, M. P., & Донцова, О. А. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912100045 · Cited by 39
Telomeres in cancer and aging: lessons from the mouse
Blasco, M. A. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00705-x · Cited by 39
Self-citationTelomere Length and Telomerase Activity Impact the UV Sensitivity Syndrome Xeroderma Pigmentosum C
Stout, G. J., & Blasco, M. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3125 · Cited by 35
“Q-FISH telomere length analysis in skin Perpendicularly cut sections of mouse skin were deparaffinised and incubated with a Cy3-labeled telomeric probe (14).”
MethodSelf-citationWang, Y., Wang, X., Flores, E. R., Yu, J., & Chang, S. S. (2016) · Aging Cell · doi:10.1111/acel.12476 · Cited by 41
“Telomeres play important roles in maintaining genome stability by preventing the activation of DNA damage checkpoints that induce p53- dependent cell cycle arrest and apoptosis (Chin et al., 1999; Artandi et al., 2000; Gonzalez-Suarez et al., 2000).”
BackgroundInfluentialThe role of DNA damage and repair in aging: New approaches to an old problem
Vijg, J. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.02.009 · Cited by 37
Harrington, L. A. (2003) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2003.12.007 · Cited by 40
Telomeric impact of conventional chemotherapy
Lu, Y., Leong, W., Guérin, O., Gilson, É., & Ye, J. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0293-z · Cited by 34
Telomere fusion to chromosome breaks reduces oncogenic translocations and tumour formation
Qi, L., Strong, M. A., Karim, B. O., Huso, D. L., & Greider, C. W. (2005) · Nature Cell Biology · doi:10.1038/ncb1276 · Cited by 32
“5781 23wk n=21 +15 t(6;13), t(12;11), t(11;14), t(13;6), t(2;4;2), t(11;3), t(1;19), t(1;13), t(9;13), t(3;4), t(19;6), t(14;6;2), t(11;16), t(t(12;11);3), t(6;19), t(4;3), t(19;18), t(17;15), t(12;14), t(10;1), f(t(12;11); 14), f(t(12;11);t(12;11)); f(15p;15p), f(17q;15p), f(15p;16p),f(15p;3p), f(11p;12p); frag(1).”
InfluentialThe Power of Stress: The Telo-Hormesis Hypothesis
Burbano, M. S. J., & Gilson, É. (2021) · Cells · doi:10.3390/cells10051156 · Cited by 41
Kotiyal, S., & Evason, K. J. (2021) · Cancers · doi:10.3390/cancers13164202 · Cited by 33
“Terc (mouse) Whole body − ↓ skin papillomas (DMBA + TPA induction) [28]”
BackgroundEvolution of genetic instability in heterogeneous tumors
Asatryan, A. D., & Komarova, N. L. (2016) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2015.11.028 · Cited by 37
“Later on, telomerase activation restores stability to allow further tumor progression, see also [46, 2, 19].”
BackgroundShort telomeres are frequent in hereditary breast tumors and are associated with high tumor grade
Martínez–Delgado, B., Gallardo, M., Tanić, M., Yanowsky, K., Inglada‐Pérez, L., Barroso, A., Rodriguez-Pinilla, M. S., Cañamero, M., Blasco, M. A., & Benitez, J. J. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2696-6 · Cited by 42
“probe, and TL was determined as described [32–36].”
MethodSelf-citation
Metadata
- Authors
- González-Suárez, E., Samper, E., Flores, J. M., & Blasco, M. A.
- Affiliations
- Centro Nacional de Biotecnología (ES)
- Universidad Complutense de Madrid (ES)
- ORCID
- Flores, Juana M.
- Venue
- Nature Genetics
- Published
- 2000-09
- Volume
- 26
- Issue
- 1
- Pages
- 114-117
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1573467049
- Cited by
- 347
- References
- 29
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 11 · 2019: 9 · 2018: 2 · 2017: 5 · 2016: 11 · 2015: 7 · 2014: 7 · 2013: 21 · 2012: 14
- FWCI
- 17.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- telomerase, telomere shortening, skin carcinogenesis, chromosomal instability, lymphoma, teratocarcinoma, epithelial tumors, telomere maintenance, malignant transformation
- MeSH terms
- Animals, Carcinogens, Flow Cytometry, Immunity, Innate, Immunohistochemistry, Mice, Inbred C57BL, Mice, Mutant Strains, Papilloma, Skin, Skin Neoplasms, Tetradecanoylphorbol Acetate, Time Factors, 9,10-Dimethyl-1,2-benzanthracene, Keratinocytes, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Telomere, In Situ Hybridization, Fluorescence, Telomerase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.